St. John's wort significantly increased the systemic exposure and toxicity of methotrexate in rats

Toxicology and Applied Pharmacology

Volumn 263, Issue 1, 2012, Pages 39-43

  Yang, Shih Ying ^a   Juang, Shin Hun ^a,b   Tsai, Shang Yuan ^a   Chao, Pei Dawn Lee ^a   Hou, Yu Chi ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hypericum perforatum; Methotrexate; Pharmacokinetics; St. John's wort

Indexed keywords

DICLOFENAC; HYPERICUM PERFORATUM EXTRACT; METHOTREXATE; PSEUDOHYPERICIN; QUERCETIN; RUTOSIDE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; FLUORESCENCE POLARIZATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG INTERACTIONS; HYPERICUM; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY;

HYPERICUM PERFORATUM; RATTUS;

EID: 84864136699     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.05.020     Document Type: Article

References (47)

1. Aquerreta I., Aldaz A., Giraldez J., Sierrasesumaga L. Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr. Blood Cancer 2004, 42:52-58.
2. Bilia A.R., Gallori S., Vincieri F.F. St. John's wort and depression: efficacy, safety and tolerability-an update. Life Sci. 2002, 70:3077-3096.
3. Borst P., Zelcer N., Van De Wetering K. MRP2 and 3 in health and disease. Cancer Lett. 2006, 234:51-61.
4. Burchini G., Orsi C. Rheumatoid arthritis. N. Engl. J. Med. 2004, 351:1360-1361. (author reply 1360-1).
5. Carneiro-Filho B., Lima I., Araujo D., Cavalcante M., Carvalho G., Brito G., Lima V., Monteiro S., Santos F., Ribeiro R. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig. Dis. Sci. 2004, 49:65-72.
6. Chen Z.S., Lee K., Walther S., Raftogianis R.B., Kuwano M., Zeng H., Kruh G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4). Cancer Res. 2002, 62:3144.
7. Dresser G.K., Schwarz U.I., Wilkinson G.R., Kim R.B. Coordinate induction of both cytochrome P4503A and MDRI by St John's wort in healthy subjects. Clin. Pharmacol. Ther.-St Louis 2003, 73:41-50.
8. Dürr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4&ast. Clin. Pharmacol. Ther. 2000, 68:598-604.
9. Ekstrom P.O., Giercksky K.E., Andersen A., Slordal L. Alterations in methotrexate pharmacokinetics by naproxen in the rat as measured by microdialysis. Life Sci. 1997, 60:PL359-PL364.
10. Endres C.J., Hsiao P., Chung F.S., Unadkat J.D. The role of transporters in drug interactions. Eur. J. Pharm. Sci. 2006, 27:501-517.
11. Erdelmeier C. Hyperforin, possible the major nonnitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998, 31:2-6.
12. Evans W.E., Crom W.R., Abromowitch M., Dodge R., Look A.T., Bowman W.P., George S.L., Pui C.H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 1986, 314:471-477.
13. Genestier L., Paillot R., Quemeneur L., Izeradjene K., Revillard J.P. Mechanisms of action of methotrexate. Immunopharmacology 2000, 47:247.
14. Grim J., Chladek J., Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin. Pharmacokinet. 2003, 42:139-151.
15. Hou Y.C., Hsiu S.L., Yen H.F., Chen C.C., Chao P.D.L. Effect of honey on naringin absorption from a decoction of the pericarps of Citrus grandis. Planta Med. 2000, 66:439-443.
16. Hou Y.C., Hsiu S.L., Huang T.Y., Yang C., Tsai S.Y., Chao P.D.L. Effect of honey and sugars on the metabolism and disposition of naringin in rabbits. Planta Med. 2001, 67:538-541.
17. Hou Y., Chao P., Ho H., Wen C., Hsiu S. Profound difference in pharmacokinetics between morin and its isomer quercetin in rats. J. Pharm. Pharmacol. 2003, 55:199-203.
18. Hsiu S.L., Huang T.Y., Hou Y.C., Chin D.H., Chao P.D.L. Comparison of metabolic pharmacokinetics of naringin and naringenin in rabbits. Life Sci. 2002, 70:1481-1489.
19. Ito K., Oleschuk C.J., Westlake C., Vasa M.Z., Deeley R.G., Cole S.P.C. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2)(ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem. 2001, 276:38108.
20. Izzo A.A. Herb-drug interactions: an overview of the clinical evidence. Fundam. Clin. Pharmacol. 2005, 19:1-16.
21. Jia J.X., Wasan K.M. Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-d-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 2008, 11:45-62.
22. Kobayashi Y., Ohshiro N., Shibusawa A., Sasaki T., Tokuyama S., Sekine T., Endou H., Yamamoto T. Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol. Pharmacol. 2002, 62:7.
23. Kool M., Van Der Linden M., De Haas M., Scheffer G.L., De Vree J.M.L., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. 1999, 96:6914.
24. Kremer J., Hamilton R. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5mg. J. Rheumatol. 1995, 22:2072-2077.
25. Kuijpers A., Van Der Kerkhof P. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am. J. Clin. Dermatol. 2000, 1:27-39.
26. Kusuhara H., Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release 2002, 78:43-54.
27. Lash L.H., Putt D.A., Cai H. Membrane transport function in primary cultures of human proximal tubular cells. Toxicology 2006, 228:200-218.
28. Nozaki Y., Kusuhara H., Kondo T., Iwaki M., Shiroyanagi Y., Nakayama H., Horita S., Nakazawa H., Okano T., Sugiyama Y. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther. 2007, 322:1162.
29. Ohtsuki S., Kikkawa T., Mori S., Hori S., Takanaga H., Otagiri M., Terasaki T. Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J. Pharmacol. Exp. Ther. 2004, 309:1273-1281.
30. Paulke A., Schubert-Zsilavecz M., Wurglics M. Determination of St. John's wort flavonoid-metabolites in rat brain through high performance liquid chromatography coupled with fluorescence detection. J. Chromatogr. B 2006, 832:109-113.
31. Piskula M.K. Factors affecting flavonoids absorption. Biofactors 2000, 12:175-180.
32. Saxena M., Henderson G.B. Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells. Biochem. Pharmacol. 1996, 51:975-982.
33. Seideman P., Beck O., Eksborg S., Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br. J. Clin. Pharmacol. 1993, 35:409.
34. Sekine T., Cha S.H., Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 2000, 440:337-350.
35. Singh Y.N. Potential for interaction of kava and St. John's wort with drugs. J. Ethnopharmacol. 2005, 100:108-113.
36. Sonneveld P., Schultz F., Nooter K., Hählen K. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother. Pharmacol. 1986, 18:111-116.
37. Takeda M., Khamdang S., Narikawa S., Kimura H., Hosoyamada M., Cha S.H., Sekine T., Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 2002, 302:666.
38. Thakrar B.T., Grundschober S.B., Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br. J. Clin. Pharmacol. 2007, 64:489-495.
39. Thyss A., Kubar J., Milano G., Namer M., Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986, 327:256-258.
40. Tirona R.G., Bailey D.G. Herbal product-drug interactions mediated by induction. Br. J. Clin. Pharmacol. 2006, 61:677-681.
41. Tracy T., Krohn K., Jones D., Bradley J., Hall S., Brater D. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol. 1992, 42:121-125.
42. Uwai Y., Okuda M., Takami K., Hashimoto Y., Inui K. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998, 438:321-324.
43. Venkataramanan R., Komoroski B., Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci. 2006, 78:2105-2115.
44. Volz H. Controlled clinical trials of Hypericum extracts in depressed patients-an overview. Pharmacopsychiatry 1997, 30:72-76.
45. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006, 11:694-703.
46. You G. (Section A: molecular, structural, and cellular biology of drug transporters) The role of organic ion transporters in drug disposition: an update. Curr. Drug Metab. 2004, 5:55-62.
47. Zeng H., Chen Z.S., Belinsky M.G., Rea P.A., Kruh G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1. Cancer Res. 2001, 61:7225.